Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Revision as of 05:48, 22 July 2020 by Jtodaro2 (talk | contribs) (Created page with "Category:Article Category:Covid19 {| class="infobox" width=200px |class="publication"|'''Publication''' |- |Title || <ul>[https://www.medrxiv.org/content/10.1101/2020....")
| Publication | |
| Title | |
| Authors |
|
| Journal | medRxiv preprint |
| Date | April 10, 2020 |
A randomized clinical trial of 62 patients who received hydroxychloroquine or standard therapy showed patients who received hydroxychloroquine had a significantly shorter time to body temperature recovery and cough remission. Notably, 4 patients (13%) in the control group progressed to severe illness whereas no patients treated with hydroxychloroquine progressed.
Major Issues
No major issues identified.
Minor Issues
No minor issues identified.
Impact
This study demonstrated some clinical benefit for hydroxychloroquine in treatment of early stage COVID-19 disease where patients received treatment on average 2.2 days after fever onset and 2 days after cough onset.
Article Revisions
None at this time.